Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProKidney Corp.

3.29
+0.03000.92%
Post-market: 3.28-0.0107-0.33%19:59 EDT
Volume:2.79M
Turnover:9.22M
Market Cap:438.93M
PE:-5.53
High:3.50
Open:3.40
Low:3.16
Close:3.26
Loading ...

Pre-Bell | US Stock Futures Rise. ProKidney Soars 57%; Verona Surges 21%; SBET up 17%; Starbucks up 3%; Ad Giant WPP Sinks 16%

Tiger Newspress
·
09 Jul

July 2025's Promising Penny Stocks To Watch

Simply Wall St.
·
09 Jul

Individual investors who hold 32% of ProKidney Corp. (NASDAQ:PROK) gained 560%, institutions profited as well

Simply Wall St.
·
09 Jul

Why Is ProKidney Stock (PROK) Up 60% Today?

TIPRANKS
·
09 Jul

ProKidney price target raised to $9 from $6 at Citi

TIPRANKS
·
09 Jul

ProKidney move after REACT update ‘looks overdone,’ says BofA

TIPRANKS
·
09 Jul

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
09 Jul

BUZZ-U.S. STOCKS ON THE MOVE-ProKidney, Eton Pharma, Datadog

Reuters
·
08 Jul

ProKidney Says Rilparencel Stabilizes Kidney Function in Phase 2 Trial

MT Newswires Live
·
08 Jul

BUZZ-ProKidney jumps on positive mid-stage data for kidney disease drug

Reuters
·
08 Jul

ProKidney Shares Rise on Positive Topline Data in Rilparencel Trial

Dow Jones
·
08 Jul

BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial

Reuters
·
08 Jul

ProKidney reports statistically significant results for Phase 2 REGEN-007 trial

TIPRANKS
·
08 Jul

ProKidney Corp. Announces Positive Topline Results for Phase 2 REGEN-007 Trial Evaluating Rilparencel in Chronic Kidney Disease Patients

Reuters
·
08 Jul

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires Live
·
01 Jul

BUZZ-BofA downgrades ProKidney on concerns about experimental kidney disease treatment

Reuters
·
30 Jun

BofA Securities Downgrades ProKidney to Underperform From Neutral, Adjusts Price Target to $1 From $3

MT Newswires Live
·
30 Jun

ProKidney Cut to Underperform From Neutral by B of A Securities

Dow Jones
·
30 Jun

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), ProKidney (PROK) and Centessa Pharmaceuticals (CNTA)

TIPRANKS
·
30 Jun

ProKidney downgraded at BofA on more conservative CKD market opportunity

TIPRANKS
·
30 Jun